Endonovo Therapeutics

Endonovo Therapeutics is a commercial-stage developer of non-invasive medical devices that deliver proprietary Electroceutical® Therapy to treat inflammatory conditions. Its strategy leverages an initial revenue-generating product, SofPulse®, while advancing a pipeline for severe chronic diseases like ischemic heart disease and traumatic brain injury. Key achievements include FDA clearance for pain and edema, CE Marking, and a pivotal CMS National Coverage Determination for chronic wounds, which significantly enhances reimbursement potential.

Proprietary Electroceutical® Therapy platform using Time-Varying Electromagnetic Fields (TVEMF) delivered via wearable device to modulate cellular ion channels and bioelectric signals, shifting the body from a pro-inflammatory to a pro-healing state.

Faces competition in wound care from advanced dressings and devices, and in bioelectronics from larger, well-funded firms like SetPoint Medical and Galvani Bioelectronics. Key advantage is an already commercialized, reimbursed product providing a revenue base and regulatory precedent.